On Friday, BTIG raised the price target for Insulet (NASDAQ:PODD) Corporation (NASDAQ: PODD) to $270 from $260, while maintaining a Buy rating on the stock. The adjustment follows Insulet's impressive third-quarter financial results, which surpassed consensus estimates and the company's own sales guidance.
Insulet reported a third-quarter revenue of $543.9 million, marking a 25.7% increase year-over-year and exceeding the consensus estimates of $519.5 million. The company's performance was particularly bolstered by robust international sales of its Omnipod product. U.S. Omnipod revenue reached $395.6 million, slightly above expectations, while international Omnipod revenue was approximately $15 million higher than anticipated at $138 million.
The company also reported drug delivery sales of $10.3 million and has raised its full-year sales guidance to between $2.036 billion and $2.053 billion, representing a 20-21% year-over-year increase. This updated guidance reflects added international strength and product launches in 10 new countries. Despite U.S. Omnipod guidance for the midpoint falling below consensus expectations, the company remains confident in achieving a growth rate in the low-20s year-over-year when excluding prior-year stocking dynamics.
Insulet has seen growth in global new customer starts both sequentially and year-over-year in the third quarter. Notably, more than 85% of new starts came from multiple daily injection (MDI) users. With the Type 2 diabetes label expansion in the U.S. in late August, the company experienced a surge in new customer starts in September, with over 25% of new U.S. starts in the third quarter coming from Type 2 diabetes patients.
The company continues to expand its salesforce, focusing on the approximately 2.5 million intensive-insulin Type 2 diabetes population. Insulet's financial health is also reflected in its adjusted gross margin of 69.3%, adjusted EBIT margin of 16.2%, and the expectation of at least 100 basis points of adjusted EBIT margin expansion annually.
In light of these financial results and the company's outlook, Thibault has adjusted sales and EPS estimates upward for Insulet Corporation. Despite stepping away from providing a 2025 outlook at this early stage, the company's strong performance in the second half of 2024 is expected to be significant for 2025 revenue. The new price target of $270 is based on applying a 7.5x EV/Sales multiple to the 12-24 month sales forecast.
In other recent news, Insulet Corporation reported a strong third quarter for 2024, with revenues reaching $543.9 million, a 25.4% increase. This surpasses both the company's and the consensus estimate. Insulet's U.S. Omnipod sales saw a 23.4% increase, driven by the FDA's approval of Omnipod 5 for Type 2 diabetes, among other factors. Internationally, sales grew by 34.8%, leading to a top market share in the markets Insulet operates in.
Despite a slight decline in Drug Delivery sales, Insulet's overall financial performance was robust, with operating margins improving to 16.2% and earnings per share coming in at $0.90, a 32.4% increase from the consensus.
In light of these results, Citi increased the shares target for Insulet to $283 from $275, while Bernstein SocGen Group set a new price target at $300. Other firms such as Canaccord Genuity and Piper Sandler have also maintained positive ratings, with raised price targets to $269 and $285 respectively.
These recent developments follow the FDA approval of Insulet's Omnipod 5 for Type 2 diabetes, the successful extension of the maturity date for its $485 million in term loans, and significant developments with its Omnipod 5 product, including its commercial launch in the U.S. with Dexcom (NASDAQ:DXCM) G7 integration.
InvestingPro Insights
Insulet Corporation's strong financial performance, as highlighted in the article, is further supported by real-time data from InvestingPro. The company's revenue growth of 27.42% over the last twelve months aligns with the impressive third-quarter results mentioned. Additionally, Insulet's robust gross profit margin of 68.78% reflects the adjusted gross margin of 69.3% reported in the article.
InvestingPro Tips indicate that Insulet is trading near its 52-week high, which is consistent with the positive market reaction to its strong financial results. The company's high return over the last year, with a one-year price total return of 58.08%, underscores investor confidence in Insulet's growth strategy and market position.
It's worth noting that while Insulet is trading at a high earnings multiple, the company's strong revenue growth and profitability metrics suggest potential for continued expansion. Investors interested in a deeper analysis can access 13 additional InvestingPro Tips for Insulet Corporation, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.